In episode 273, Mike and James break down even more evidence around treatments for osteoarthritis. In this episode, we discuss topical NSAIDs, alternative therapies, narcotics and conclude, as in the previous podcast, that it is ultimately up to the patient to try to figure out what works best for them.
Show notes
In episode 272, Mike and James break down all the evidence around treatments for osteoarthritis. In this episode, we discuss activity, acetaminophen, NSAIDs and the benefits and harms around these treatments and at the end we come to the conclusion that it is ultimately up to the patient to try to figure out what works best for them.
Show notes
In episode 271, James and Mike discuss the most recent evidence for two new monoclonal antibody medications that lower lipids. We discuss the two new studies OSLER and ODYSSEY. At the end we both agree that it is great these studies looked at cardiovascular events and at least they are going in the right direction. However, we still have a long way to go before we would consider using them.
Show notes
Study synopses can be found at mystudies.org
DESCARTES
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
OSLER
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
ODYSSEY LONG TERM
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
In episode 270, the Mikes and Tina and James stay viral, and discuss the best available evidence around the use of antiviral medications for treatment of the flu. At the end, we all agree there is an effect and that the person who should make the decision should be the patient once they have had the benefits and harms appropriately explained. Shared decision-making, a concept that is certainly nothing to be sneezed at.
Show notes
1) Tools for Practice
Anti-virals for Flu: Looking for evidence for “Stockpile, store, expire, repeat”
In episode 269, the Mikes and James go viral on the HPV vaccine. We discuss what the evidence shows around the use of the HPV vaccine in females and males and in contrast to many people, we actually present the numbers so that you can help people, or help yourself make decisions.
Show notes
1) Tools for Practice
In episode 268, Mike and James discuss the use of benzodiazepines in the management of agitation in demented elders. We discuss the evidence and realise that the evidence is at best iffy. Nonetheless, they seem to be as effective as antipsychotics but both classes of drugs have side effects and should be used in low doses and stopped as soon as possible.
Show notes
1) Tools for Practice
In episode 267, James and Mike finally get to the first PREMIUM podcast of 2015 – and boy is it something. We discuss a new paper put out by the Edmonton gang on who actually contributes to primary care guidelines, we talk about a new systematic review of mild hypertension treatment, and finally discuss a NEJM article on the duration of dual antiplatelets. At the end we both agree this podcast was really something.
Show notes
1) Contributors to primary care guidelines
Can Fam Physician 2015;61:52-8
2) Effects of Blood Pressure Reduction in Mild Hypertension
A Systematic Review and Meta-analysis
Ann Intern Med. 2015;162(3):184-191. doi:10.7326/M14-0773
3) Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
In episode 266, James and Mike finally get to the end of listener questions. We talk about NSAIDs and inflammation, cognitive impairment and statins, dosing of antibiotics, antidepressants and efficacy, and antiplatelets and ethnicity. We give answers which either clarify or confuse the issues.
Show notes
1) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2) Selective publication of antidepressant trials and its influence on apparent efficacy
3) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics
In episode 265, Mike and James continue with listener questions. We tackle issues around calories, alcohol intake, nutrition, diabetes and so much more. We provide answers and so much less.
Show notes
1) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis
In episode 264, James and Mike continue trying to answer listener questions. We tackle issues around blood viscosity, nutrition, and diabetes medications with abandon, and hopefully provide some useful information.
Show notes
THE NUTRITION PROPOSITION BOOK
Check it out at nutritionproposition.com and think about picking up a copy on Amazon. All the evidence you ever wanted about nutrition and the only nutrition book that won’t tell you what to eat.
This pragmatic trial is now recruiting in BC. Make a difference and get involved with pragmatic trials (www.pragmatictrials.ca)
